• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Rivaroxaban does not prevent cardiovascular events in rheumatic heart disease patients with atrial fibrillation

byBryant LimandKiera Liblik
September 15, 2022
in Cardiology, Chronic Disease, Hematology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Rivaroxaban was not associated with a lower rate of cardiovascular events and death compared to vitamin K antagonist treatment in patients with rheumatic heart disease-associated atrial fibrillation. 

2. There was no significant differences between groups in the incidence of major bleeding safety outcomes.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Previous randomized trials have demonstrated the efficacy of non-vitamin K antagonist oral coagulants, such as the factor Xa inhibitor rivaroxaban, for stroke prevention in patients with atrial fibrillation. Compared to vitamin K antagonist treatment, Rivaroxaban treatment does not require regular blood sampling to monitor anticoagulation status. However, these trials have largely excluded patients with rheumatic heart disease. This randomized control trial evaluated the efficacy and safety of rivaroxaban for preventing cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation. Patients were followed for an average of 3.1 years. The incidence of a primary outcome event, defined as a composite of stroke, systemic embolism, myocardial infarction, or death, was higher in the rivaroxaban compared to the vitamin K antagonist group. Mortality was higher in the rivaroxaban group, owing to higher rates of sudden cardiac death or mechanical or pump failure. Rates of hospitalization for heart failure and valvular replacement surgery were not significantly different between groups. There were no significant differences in rates of major bleeding, the primary safety outcome, between groups. As a limitation, there was a higher incidence of discontinuation of rivaroxaban than vitamin K antagonist, which may lead to more cardiovascular events in the rivaroxaban group. In addition, outcome measures had to be redefined during the trial due to lower rates of cardiovascular events than expected.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: In the present randomized control trial, adults aged 18 and over with documented atrial fibrillation and echocardiographically-confirmed rheumatic heart disease (n=4,531) were recruited at 138 trial sites in Africa, Asia, and Latin America. Patients were randomly assigned in a 1:1 ratio to receive either rivaroxaban (n=2,275) or a locally available vitamin K antagonist (n=2256). According to renal function, Rivaroxaban was administered at a daily dose of 15 or 20mg. The most administered vitamin K antagonist was warfarin (79 to 85% of patients in the group). Patients were followed for up to one month after randomization and every six months afterward for a mean follow-up of 3.1 (standard deviation, 1.2) years. The incidence of trial discontinuation was higher in the rivaroxaban group compared to the vitamin K antagonist group (79.0% and 96.4% adherence respectively at year four). A primary-outcome event, defined as stroke, systemic embolism, myocardial infarction, or death, occurred in 560 and 446 patients in the rivaroxaban and vitamin K antagonist groups, respectively (proportional-hazards ratio, 1.25; 95% Confidence Interval [CI], 1.10 to 1.41). For secondary outcomes, both incidences of stroke (90 and 65 patients in the rivaroxaban and vitamin K antagonist groups, respectively) and mortality (difference in restricted mean survival time, -72 days; 95% CI, -117 to -28) were higher in the rivaroxaban group. Rates of hospitalization for heart failure or valvular replacement surgery were not significantly different between groups. There were no significant differences in rates of major bleeding. Results from this trial support current guidelines that recommend vitamin K antagonists, and not rivaroxaban, for stroke prevention in patients with rheumatic heart disease-associated atrial fibrillation.

Image: PD

RELATED REPORTS

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: arrhythmiaatrial fibrillationcardiologychronic diseasefactor Xa inhibitorhematologyrheumatic heart diseaserivaroxabanvitamin K antagonistwarfarin
Previous Post

HELLP syndrome is variant of preeclampsia [Classics Series]

Next Post

Human papillomavirus infection is associated with adenocarcinoma of the cervix [Classics Series]

RelatedReports

β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

January 26, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Human papillomavirus infection is associated with adenocarcinoma of the cervix [Classics Series]

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization

Polypill strategy reduces the risk of cardiovascular events after a myocardial infarction

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Wellness Check: Sleep

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options